BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 20210927)

  • 1. Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents.
    Klarmann D; Eggert C; Geisen C; Becker S; Seifried E; Klingebiel T; Kreuz W
    Transfusion; 2010 Jul; 50(7):1571-80. PubMed ID: 20210927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.
    Favaloro EJ; Soltani S; McDonald J; Grezchnik E; Easton L; Favaloro JW
    Am J Clin Pathol; 2005 Dec; 124(6):910-7. PubMed ID: 16416741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals.
    Schleef M; Strobel E; Dick A; Frank J; Schramm W; Spannagl M
    Br J Haematol; 2005 Jan; 128(1):100-7. PubMed ID: 15606555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens.
    Morelli VM; de Visser MC; van Tilburg NH; Vos HL; Eikenboom JC; Rosendaal FR; Bertina RM
    Thromb Haemost; 2007 Apr; 97(4):534-41. PubMed ID: 17393014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ABO blood group on the collagen-binding assay for von Willebrand factor.
    Haley E; Babar N; Ritter C; Downes KA; Green D; Shurin S; Sarode R
    Am J Hematol; 2002 Nov; 71(3):229-31. PubMed ID: 12410584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of the ABO blood type on the distribution of von Willebrand factor in healthy children with no bleeding symptoms.
    Akin M; Balkan C; Karapinar DY; Kavakli K
    Clin Appl Thromb Hemost; 2012 Jun; 18(3):316-9. PubMed ID: 21949039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women.
    Ay C; Thom K; Abu-Hamdeh F; Horvath B; Quehenberger P; Male C; Mannhalter C; Pabinger I
    Haemophilia; 2010 Jan; 16(1):111-7. PubMed ID: 19758307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Content and functional activity of von Willebrand factor in apheresis plasma.
    Burnouf T; Caron C; Burkhardt T; Goudemand J
    Vox Sang; 2004 Jul; 87(1):27-33. PubMed ID: 15260819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?
    Jenkins PV; O'Donnell JS
    Transfusion; 2006 Oct; 46(10):1836-44. PubMed ID: 17002642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.
    Favaloro EJ; Bukuya M; Martinelli T; Tzouroutis J; Duncan E; Welldon K; Collecutt M; Aumann H; Thom J; Gilmore G
    Thromb Haemost; 2002 Mar; 87(3):466-76. PubMed ID: 11916080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hemostatic profiles of patients with Type O and non-O blood after acute normovolemic hemodilution with 6% hydroxyethyl starch (130/0.4).
    Kang JG; Ahn HJ; Kim GS; Hahm TS; Lee JJ; Gwak MS; Choi SJ
    Anesth Analg; 2006 Dec; 103(6):1543-8. PubMed ID: 17122237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes.
    Lethagen S; Hillarp A; Ekholm C; Mattson E; Halldén C; Friberg B
    Thromb Haemost; 2008 Jun; 99(6):1013-8. PubMed ID: 18521502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease.
    Böhm M; Täschner S; Kretzschmar E; Gerlach R; Favaloro EJ; Scharrer I
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):39-45. PubMed ID: 16607078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.